Share this page!

#TumorBoardTuesday Profile picture
Twitter logo
Dec 15 • 6 tweets • 9 min read
1/🛎️#TumorBoardTuesday #OncTwitter #NephTwitter
#RenalCell wk continues🔁

🗓️Thu 12.15 @ 8p ET

⚙️Mnging AEs w TKI/IO combos

#CME ℹ️🔗bit.ly/3iLN6aX
Supported by edu grants from Eisai & @Merck
🚨Be ready 4 tmrw!
✅Answer #PreTest polls👇
🔁Retweet & tag colleagues🩺
2/ 🏆Claim 🆓#CME 🔛 bit.ly/3iLN6aX

Answer Pre Polls Qs 👇today
🟢Where r u in your career?
3/ #TumorBoardTuesday #RenalCell #NephTwitter #MedTwitter #BonumCE

#CME🔗bit.ly/3FbuEQx

🟢#PreTest Q 1️⃣
📊 Which of the following is a common high-grade toxicity associated with the use of TKIs in the management of metastatic RCC?
4/ #TumorBoardTuesday #RenalCell #NephTwitter #MedTwitter #BonumCE

#CME 🔗 bit.ly/3FbuEQx

🟢#PreTest Q 2️⃣
📊 Which of the following is NOT a characteristic of immune-mediated toxicities associated with the use of ICIs?
5/ #TumorBoardTuesday #RenalCell #NephTwitter #MedTwitter #BonumCE

#CME 🔗bit.ly/3FbuEQx

🟢#PreTest Q 3️⃣
📊 Pt treated w/ combo of pembro & lenvatinib for mRCC develops grade 3 diarrhea. How might you diagnose which drug is causing this toxicity?
6/ #TumorBoardTuesday #RenalCell #NephTwitter

🟢#PreTest Q 4️⃣
📊Pt treated w/ combo of cabo + nivo develops G3 HTN. Cabo therapy is held & pt receives anti-hypertensive medication & BP recovers to baseline. At what dose can cabozantinib be restarted?

• • •

Missing some Tweet in this thread? You can try to force a refresh
　

Keep Current with #TumorBoardTuesday

#TumorBoardTuesday Profile picture

Stay in touch and get notified when new unrolls are available from this author!

Read all threads

This Thread may be Removed Anytime!

PDF

Twitter may remove this content at anytime! Save it as PDF for later use!

Try unrolling a thread yourself!

how to unroll video
  1. Follow @ThreadReaderApp to mention us!

  2. From a Twitter thread mention us with a keyword "unroll"
@threadreaderapp unroll

Practice here first or read more on our help page!

More from @TumorBoardTues

#TumorBoardTuesday Profile picture
Dec 13
1/ #OncTwitter #NephTwitter #TumorBoardTuesday
✅#RenalCell #MedTweetorial🧵
w @brian_rini @shilpaonc @katy_beckermann

🦺TKI/IO safety data
🥽Tox to look 4
⛑AE mgmt

🆓#CME @BonumCe🔗bit.ly/3VDaK81
Support by edu grants from Eisai & @Merck

🟢What's your specialty?
2/ #TumorBoardTuesday #BonumCE #RenalCell #OncTwitter #NephTwitter
🆓#CME info ➕ full ref list🗒️ 👉 bit.ly/3VDaK81

✳️The critical elements👇 Image
3/ #TumorBoardTuesday #BonumCE #RenalCell
#OncTwitter #NephTwitter #MedTwitter

🟢 Which of the following TKI/IO combo regimens is 🚫NOT approved by the FDA for the frontline mgmt of #RenalCell carcinoma?
Read 27 tweets
#TumorBoardTuesday Profile picture
May 30
#TumorBoardTuesday #ASCO2022

📢@ASCO is only a few days away & we really wanted to put out our top abstracts to👀for

🙏note - we viewed several thousand titles - so we definitely may have missed some‼️
👉And these are not in any particular order

✅But enjoy, RT, and reply😀
#TumorBoardTuesday #ASCO2022
"Emerging"🎯💊
✅Dr. Jones👨‍🏫the Ph2 FAKTION trial of fulv/capi vs fulv/placebo for Breast Ca
➡️Capi⬆️mOS by 6 mos
➡️This⬆️jumped to 19 ms if the tumor harbored PIK3CA or AKT1 activating OR PTEN inactivating🧬mutations
🔎Breast Ca Oral Abstract # 1005
#TumorBoardTuesday #ASCO2022
"Emerging"🎯💊
✅Dr. Rixe👨‍🏫PhI data4⃣OBT076, an ADC🎯the CD205/Ly75 Ag - a receptor⬆️on immunosuppressive dendritic cells
➡️1⃣PR & 6⃣SD out of 2⃣0⃣pts
➡️Near CR in 2⃣pts who then had pembro
🤔Why wasn't☝️more than a poster❓
🔎Abs 3028, Poster 20
Read 32 tweets
#TumorBoardTuesday Profile picture
May 25
🙏🏽Thank you @Latinamd @GDutcherMD for an informational & exhilarating #TumorBoardTuesday!!

🏆Remember 🆓CME

Look for the Case Wrap Up🎀 05/26/22

📅Mark your calendar for 𝙉𝙀𝙓𝙏 𝙒𝙀𝙀𝙆 05/31/22 when our own @MPishvaian joins us for a breakdown of #ASCO22 abstracts!!
🏝#TumorBoardTuesday education is beyond Twitter - we offer🆓CME!!

🫁Before you run off exploring, pick up your🏆#CME by answering quick questions regarding a case similar to @Latinamd’s‼️

🔗ALL CME: integrityce.com/tbt

🔗CME eval: integrityce.com/TBTEval

👇🏽🎁
#PostTest Q1️⃣ #CME #TumorBoardTuesday

🔗CME eval: integrityce.com/TBTeval

🫁@Latinamd @GDutcherMD took us through a case of MET exon 14 skip mutation #NSCLC - test your 🧠with these quick❓

🧐How common are METex14-skipping mutations in NSCLC (Non-Small Cell Lung Cancer)?
Read 6 tweets
#TumorBoardTuesday Profile picture
May 23
#TumorBoardTuesday

🎓We have had some highly educational🗣️on tumor biomarkers
👍This week’s conversation will NOT disappoint

📢Join us as @Latinamd & @GDutcherMD from @SylvesterCancer discuss MET Exon 14 skip mutations in #NSCLC #Miami Image
#TumorBoardTuesday

@Latinamd & @GDutcherMD @TumorBoardTues 🗣️
📅Tuesday, 05/24/22 at🕗8PM ET
📊✅the polls
⚖️in & bring citations🧾
🔁Retweet & tag your🩺colleagues
🏆Earn your🆓CME and MOC integrityce.com/tbt

And B4⃣the case:
🧐tell us where you are in your🩺journey
👇
#TumorBoardTuesday

#PreTest Q 1⃣ #CME
Free CME 🔗: integrityce.com/tbt

🤔Before @Latinamd & @GDutcherMD🚶us through a case of MET Exon 14 skip mutations in #NSCLC, test your🧠with these 4 quick❓

How common are METex14-skipping mutations in Non-Small Cell Lung Cancer❓
Read 6 tweets
#TumorBoardTuesday Profile picture
May 20
1/12 #TumorBoardTuesday
2L treatment in #HER2+ breast cancer #MBC is 🤯! @PTarantinoMD led us through latest evidence👩‍⚖️

➡️Here's the Thurs Case🎀
👉Grab🆓 #CME credit by answering quick❓
ALL CME 🔗: integrityce.com/tbt
CME rationale🔗: bit.ly/3NnreMW
Here we go!
2/12 #TumorBoardTuesday
Thurs Case🎀

Take🏠messages:
⬆️ options to tx HER2+ #MBC
✅T-DXd >T-DM1 in 2L setting (DESTINY BREAST-03)
✅Beware ADC tox- think 🫁pneumonitis & GI w T-Dxd
✅ADC design is 🗝:
➡️Need to consider DAR, linker, ability to cause ADCC
✅ADC + IO= open ❓
3/12 #TumorBoardTuesday
Thurs Case🎀

Take🏠messages (cont’d):
✅T-DXd active against brain mets (TUXEDO-1)
✅Triplet (tucatinib, cape, tras) also active in brain mets
✅Next up: T-DXd in HER2 LOW- trials ongoing

📚We captured the discussion here:
twitter.com/i/events/15226…
Read 15 tweets
#TumorBoardTuesday Profile picture
May 13
1/12 #TumorBoardTuesday

🔬🧬Discussion on #ColonCancer and BRAFv600E disease w dMMR led by @FlavioRochaMD
➡️Here is this week's Thurs Case🎀

👉👉 Don’t forget to pick up🆓 #CME credit by answering 2 quick ❓
ALL CME 🔗: integrityce.com/tbt
Now…we’re off to the races!
2/11 #TumorBoardTuesday
Thurs Case🎀

Take🏠messages:
#CRC 🚫one disease!
✅Diff 🧬subtypes that define tx sensitivity
✅BRAFv600E is bad–but may be ⬆️sensitive to IO w MLH1 meth
✅Neoadj tx: 🦊FOXTROT= poss benefit, depends on subgroup
✅Keynote177: IO= way to go in dMMR!
3/12 #TumorBoardTuesday
Thurs Case🎀

Take🏠messages (cont’d):

✅ATOMIC will help answer ❓chemo/IO combo upfront is best in dMMR and BRAFv600E
✅POLEM trial also looking at adjuv IO in dMMR @shafiarahman_

📚We captured the discussion in this moment: twitter.com/i/events/15212…
Read 18 tweets

Did Thread Reader help you today?

Support us! We are indie developers!

This site is made by just two indie developers on a laptop doing marketing, support and development! Read more about the story.

Become a Premium Member ($3/month or $30/year) and get exclusive features!

Become Premium

Don't want to be a Premium member but still want to support us?

Make a small donation by buying us coffee ($5) or help with server cost ($10)

Donate via Paypal

Or Donate anonymously using crypto!

Ethereum

0xfe58350B80634f60Fa6Dc149a72b4DFbc17D341E copy

Bitcoin

3ATGMxNzCUFzxpMCHL5sWSt4DVtS8UqXpi copy

Thank you for your support!

Follow Us on Twitter!

Send Email!

:(